Aptevo Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
65
- Stock Symbol
-
APVO
- Share Price
-
$5.51
- (As of Friday Closing)
Aptevo Therapeutics General Information
Description
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Contact Information
Website
www.aptevotherapeutics.comCorporate Office
- 2401 4th Avenue
- Suite 1050
- Seattle, WA 98121
- United States
Corporate Office
- 2401 4th Avenue
- Suite 1050
- Seattle, WA 98121
- United States
Aptevo Therapeutics Stock Performance
As of 23-May-2025, Aptevo Therapeutics’s stock price is $5.51. Its current market cap is $44.7M with 8.11M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.51 | $6.00 | $4.85 - $658.60 | $44.7M | 8.11M | 245K | -$52.9K |
Aptevo Therapeutics Financials Summary
As of 31-Mar-2025, Aptevo Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 29,751 | 122,795 | 54,663 | 224,208 |
| Revenue | 0 | 0 | 0 | 3,114 |
| EBITDA | (23,397) | (23,778) | (18,083) | 7,915 |
| Net Income | (23,704) | (24,130) | (17,411) | 8,027 |
| Total Assets | 8,342 | 15,591 | 24,842 | 34,215 |
| Total Debt | 4,422 | 4,629 | 5,397 | 9,535 |
Aptevo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aptevo Therapeutics Comparisons
Industry
Financing
Details
Aptevo Therapeutics Competitors (68)
One of Aptevo Therapeutics’s 68 competitors is Senti Bio, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Senti Bio | Formerly VC-backed | South San Francisco, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| ALX Oncology | Formerly VC-backed | San Francisco, CA | ||||
| Surrozen | Formerly VC-backed | South San Francisco, CA |
Aptevo Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aptevo Therapeutics Patents
Aptevo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3219832-A1 | Dosing regimens for protein therapeutics | Pending | 21-May-2021 | ||
| AU-2022276523-A1 | Dosing regimens for protein therapeutics | Pending | 21-May-2021 | ||
| US-20240262920-A1 | Dosing regimens for protein therapeutics | Pending | 21-May-2021 | ||
| EP-4341291-A1 | Dosing regimens for protein therapeutics | Pending | 21-May-2021 | ||
| AU-2022223692-A1 | Compositions comprising 4-1bb and ox40 binding proteins and methods of use | Pending | 17-Feb-2021 | C07K16/2878 |
Aptevo Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aptevo Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aptevo Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Aptevo Therapeutics FAQs
-
When was Aptevo Therapeutics founded?
Aptevo Therapeutics was founded in 2016.
-
Where is Aptevo Therapeutics headquartered?
Aptevo Therapeutics is headquartered in Seattle, WA.
-
What is the size of Aptevo Therapeutics?
Aptevo Therapeutics has 65 total employees.
-
What industry is Aptevo Therapeutics in?
Aptevo Therapeutics’s primary industry is Biotechnology.
-
Is Aptevo Therapeutics a private or public company?
Aptevo Therapeutics is a Public company.
-
What is Aptevo Therapeutics’s stock symbol?
The ticker symbol for Aptevo Therapeutics is APVO.
-
What is the current stock price of Aptevo Therapeutics?
As of 23-May-2025 the stock price of Aptevo Therapeutics is $5.51.
-
What is the current market cap of Aptevo Therapeutics?
The current market capitalization of Aptevo Therapeutics is $44.7M.
-
Who are Aptevo Therapeutics’s competitors?
Senti Bio, CytomX Therapeutics, NexImmune, ALX Oncology, and Surrozen are some of the 68 competitors of Aptevo Therapeutics.
-
What is Aptevo Therapeutics’s annual earnings per share (EPS)?
Aptevo Therapeutics’s EPS for 12 months was -$52.9K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
